Literature DB >> 27424358

The Role of Surgery in the Management of Gestational Trophoblastic Neoplasia The Hungarian Experience.

Vilmos Fülöp, Iván Szigetvári, János Szepesi, György Végh, László Zsirai, Ross S Berkowitz.   

Abstract

OBJECTIVE: To review the role of surgery in the management of gestational trophoblastic neoplasia (GTN) over the past 38 years in our national trophoblastic disease center. STUDY
DESIGN: Between January 1, 1977, and December 31, 2014, 371 patients with low-risk GTN and 190 patients with high-risk GTN were treated with chemotherapy, surgical interventions, or both. The indications for hysterectomy included excision of large uterine tumor masses, uterine hemorrhage or sepsis, or a drug-resistant uterine focus. Metastases were excised due to the presence of drug-resistant foci or complications of disease such as hemorrhage.
RESULTS: Over the period of 1977-2014 74 hysterectomies, 15 resections of vaginal metastases, 3 omentectomies, 13 adnexectomies, 9 lung resections, I nephrectomy, 1 lung resection and nephrectomy, and 2 craniotomies were performed among our patients. While hysterectomy was performed in 51 (26.8%) of 190 high-risk patients, hysterectomy was performed in only 23 (6.2%) of 371 low-risk patients (p < 0.01). From 1977-2006 metastases were resected in 18.3% (26/142) and from 2007-2014 in 16.7% (8/48) of high-risk patients.
CONCLUSION: In our center surgery, particularly in the form of hysterectomy, still plays a valuable role in the management of both low- and high-risk GTN.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27424358

Source DB:  PubMed          Journal:  J Reprod Med        ISSN: 0024-7758            Impact factor:   0.142


  1 in total

1.  Management and prognosis of patients with liver metastases from gestational trophoblastic neoplasia: a retrospective cohort study.

Authors:  Liju Zong; Junjun Yang; Xiaoyu Wang; Yujia Kong; Tong Ren; Jun Zhao; Fengzhi Feng; Xirun Wan; Yang Xiang
Journal:  Cancer Manag Res       Date:  2018-03-23       Impact factor: 3.989

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.